Bigelovin

Name: Bigelovin
Brand: MedChemExpress
SKU: HY-116506
Rating: 4.5 (1 reviews)

Cat. No.: HY-116506 Purity: 99.92%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Bigelovin, a sesquiterpene lactone isolated from Inula hupehensis, is a selective retinoid X receptor α agonist. Bigelovin suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation.

For research use only. We do not sell to patients.

Bigelovin Chemical Structure

CAS No. : 3668-14-2

Size	Price	Stock	Quantity
5 mg	USD 280	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 370	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All RAR/RXR Isoform Specific Products:

View All Isoforms

RXRα RXRβ RXRγ

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	ED₅₀	4.9 μM Compound: Bigelovin	Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal after 24 to 48 hrs by luciferase reporter gene assay Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal after 24 to 48 hrs by luciferase reporter gene assay	[PMID: 24959987]
HMEC-1	IC₅₀	2679.2 nM Compound: Bigelovin	Inhibition of HMEC1 cells growth measured after 48 hrs by MTT assay Inhibition of HMEC1 cells growth measured after 48 hrs by MTT assay	[PMID: 23231968]
HMEC-1	IC₅₀	946.2 nM Compound: Bigelovin	Inhibition of HMEC1 cells growth measured after 48 hrs Inhibition of HMEC1 cells growth measured after 48 hrs	[PMID: 23231968]
MCF-10A	IC₅₀	26 μM Compound: 14	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MCF7	IC₅₀	2.1 μM Compound: 14	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MDA-MB-231	IC₅₀	2.3 μM Compound: 14	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
RAW264.7	IC₅₀	0.9 μM Compound: 13	Antiinflammatory action in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 30 mins before LPS challenge measured after 24 hrs by griess reaction Antiinflammatory action in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 30 mins before LPS challenge measured after 24 hrs by griess reaction	[PMID: 21894898]

In Vitro

Bigelovin (0-20 μM, 24-72 h) significantly inhibits cell viability of liver cancer cells and induces apoptosis and autophagy^[1].
Bigelovin causes a significant increase of p62, LC3B-II, Beclin-1 and a corresponding decrease of p62 levels in a time-dependent manner^[1].
Bigelovin induces cell death involves the suppression of mTOR pathway regulated by ROS production^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HepG2 and SMMC-7721 cells.
Concentration:	0-20 μM.
Incubation Time:	24, 48, 72 h.
Result:	Significantly reduced the cell viability of HepG2 and SMMC-7721 cells in a dose- and time dependent manner. No significant difference observed in cell viability of normal liver cell lines, LO2 and LX2, after BigV treatment for 24, 48 or 72 h.

Western Blot Analysis^[1]

Cell Line:	HepG2 and SMMC-7721 cells.
Concentration:	0-10 μM.
Incubation Time:	24 h.
Result:	The expression of Bcl-2 was decreased, whereas Bax was increased after treatment with BigV. Moreover, Caspase-9, -3 and PARP cleavage were activated significantly after BigV treatment.

In Vivo

Bigelovin (BigV, 5, 10, 20 mg/kg) exerts anti-tumor activity in HepG2 xenograft tumor model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HepG2 xenograft model based on the male athymic BALB/c nude mice (5-6 weeks old, 18-22 g)^[1].
Dosage:	5, 10, 20 mg/kg.
Administration:	Intravenous injection every 2 days.
Result:	The tumor growth rate was significantly slower in BigV treated groups in a dose-dependent manner, along with the reduced tumor weight. No significant alteration of body weight and hepatic enzyme levels (AST, ALT and LDH) in serum was observed after BigV administration. Western blot findings of tumor tissues indicated the activation of apoptosis and autophagy characterized by the increase of cleaved Caspase-3 and PARP, as well as LC3BII levels. The inactivation of mTOR was also observed in tumor tissues isolated from BigV-treated mice.

Molecular Weight

304.34

Formula

C₁₇H₂₀O₅

CAS No.

3668-14-2

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12C(C=C[C@]1([C@@H](C[C@]3([C@H]([C@@H]2OC(C)=O)C(C(O3)=O)=C)[H])C)[H])=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (328.58 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2858 mL	16.4290 mL	32.8580 mL
5 mM	0.6572 mL	3.2858 mL	6.5716 mL
10 mM	0.3286 mL	1.6429 mL	3.2858 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (286 KB) SDS (251 KB)

COA (273 KB) HNMR (270 KB) LCMS (87 KB)

Handling Instructions (2659 KB)

References

[1]. Bei Wang, et al. Bigelovin, a sesquiterpene lactone, suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation in liver cancer. Biochem Biophys Res Commun. 2018 May 5;499(2):156-163. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2858 mL	16.4290 mL	32.8580 mL	82.1450 mL
	5 mM	0.6572 mL	3.2858 mL	6.5716 mL	16.4290 mL
	10 mM	0.3286 mL	1.6429 mL	3.2858 mL	8.2145 mL
	15 mM	0.2191 mL	1.0953 mL	2.1905 mL	5.4763 mL
	20 mM	0.1643 mL	0.8214 mL	1.6429 mL	4.1072 mL
	25 mM	0.1314 mL	0.6572 mL	1.3143 mL	3.2858 mL
	30 mM	0.1095 mL	0.5476 mL	1.0953 mL	2.7382 mL
	40 mM	0.0821 mL	0.4107 mL	0.8214 mL	2.0536 mL
	50 mM	0.0657 mL	0.3286 mL	0.6572 mL	1.6429 mL
	60 mM	0.0548 mL	0.2738 mL	0.5476 mL	1.3691 mL
	80 mM	0.0411 mL	0.2054 mL	0.4107 mL	1.0268 mL
	100 mM	0.0329 mL	0.1643 mL	0.3286 mL	0.8214 mL

Bigelovin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bigelovin3668-14-2RAR/RXRReactive Oxygen SpeciesApoptosisAutophagyRetinoic acid receptorsRetinoid X receptorsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Bigelovin

Customer Review

Bigelovin Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All RAR/RXR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Bigelovin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Bigelovin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report